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Worldwide, gastric cancer is one of the most common forms of cancer, with a high morbidity and mortality. Several
environmental factors predispose to the development of gastric cancer, such as Helicobacter pylori infection, diet
and smoking. Familial clustering of gastric cancer is seen in 10% of cases, and approximately 3% of gastric cancer
cases arise in the setting of hereditary diffuse gastric cancer (HDGC). In families with HDGC, gastric cancer presents
at relatively young age. Germline mutations in the CDH1 gene are the major cause of HDGC and are identified in
approximately 25-50% of families which fulfill strict criteria. Prophylactic gastrectomy is the only option to prevent
gastric cancer in individuals with a CDH1 mutation. However, in the majority of families with multiple cases of
gastric cancer no germline genetic abnormality can be identified and therefore preventive measures are not
available, except for general lifestyle advice. Future research should focus on identifying new genetic predisposing
factors for all types of familial gastric cancer.
Keywords: Gastric cancer, Genetics, Hereditary diffuse gastric cancer, CDH1, E-cadherinGeneral introduction
With an estimated 900,000 new cases per year (8.6% of
all new cancer cases except skin cancer), gastric cancer
(GC) is the fourth most common form of cancer world-
wide. Even though the incidence is rapidly declining in
the western world, it is still the second most common
cause of death from cancer, with 740,000 deaths annually
and a 5-year survival of 20% [1]. High-risk areas include
East Asia (Japan, China and Korea), Eastern Europe, and
parts of Central and South America. Incidence rates are
low in North Europe, North America and Australia [1].
With a mean age at diagnosis above 60 years, gastric
cancer is predominantly a disease of the elderly [2]. Only
6–7% of patients with gastric cancer present before the
age of 50, and less than 2% before age 40 [2,3].
Gastric carcinoma is a heterogeneous disease, which is
reflected by the diversity of the various histopathological
classification schemes [4]. The most commonly used are
those of the WHO [4] and Laurén [5]. The practical* Correspondence: n.hoogerbrugge@gen.umcn.nl
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reproduction in any medium, provided the orscheme of Laurén divides GC roughly into three main
types; the diffuse type, the intestinal type and a rest
group composed of mixed and indeterminate type [5].
Intestinal GC shows glandular or tubular components
with various degrees of differentiation. Diffuse GC
consists of poorly cohesive single cells without gland
formation. Often signet ring cells are present; therefore
it is also referred to as signet ring cell carcinoma [4].
In North America the distribution of the different sub-
types is approximately 50% pure intestinal, 35% pure
diffuse and 15% mixed diffuse-intestinal [6].Etiology of gastric cancer: environmental factors
Gastric cancer is a multifactorial disease, resulting
from a combination of environmental factors and gen-
etic alterations. Environmental factors are mainly
involved in the etiology of the intestinal type of GC.
The main environmental factor involved is Helicobacter
pylori (H.Pylori) infection, which is commonly acquired
during childhood and persists unless eradicated [7]. H.
Pylori can induce a sequence of gastritis, intestinal
metaplasia, dysplasia and eventually gastric cancer [8].
A meta-analysis of 12 studies revealed that infection
with H.pylori increases the risk of developing GCal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as a class I carcinogen in 1994 [10,11].
Cigarette smoking is an important behavioral risk fac-
tor for the development of GC. A large systematic re-
view of 42 studies showed that the risk of GC is
increased by 60% in male and 20% in female smokers
compared to never smokers [12]. Smoking also enhances
the carcinogenic effect of infection with H.pylori [13].
Another important risk factor for the development of
GC is diet. An adequate intake of fruit and vegetables
likely reduces the risk for developing GC [4]. Salt intake,
on the other hand, is strongly associated with an
enhanced risk to develop gastric carcinoma. Therefore,
diet adjustments that reduce salt intake, for instance
after replacement of salt preservation of food by refrig-
erators, are important factors in the decrease of the inci-
dence of GC, [4]. Smoked meat and fish, pickled
vegetables and chili peppers are also associated with GC
in some populations [4]. Alcohol consumption has been
studied in several populations, but results have been in-
conclusive [4].
The incidence of GC is declining worldwide, which is
mainly due to the decline in the incidence of the distal,
intestinal type of GC. The incidence of diffuse GC, for
which no clear environmental risk factors are known,
has not decreased [4]. In young people, in whom carcin-
omas are more likely to be due to genetic susceptibility,
a greater proportion shows the diffuse type, suggesting
that especially in this subtype germline genetics play a
role [4].
Etiology of gastric cancer: genetic factors
Familial aggregation of gastric cancer is known to occur
in approximately 10% of the patients [14]. Epidemiologic
studies have shown that in the general population the
risk of gastric cancer in first-degree relatives with any
type of gastric cancer is increased 2–3 fold [15]. As yet,
however, in the vast majority of these patients the under-
lying genetic cause remains unknown. The most import-
ant GC susceptibility gene is CDH1, which accounts for
1-3% of gastric cancers [16]. Predisposing CDH1 muta-
tions have been encountered in about 30% of strictly
selected Hereditary Diffuse Gastric Cancer (HDGC)
families [17,18]. Moreover, CDH1 germline mutations
may also occur in approximately 7% of patients diag-
nosed before 50 years of age with tumors exhibiting ei-
ther a diffuse or a mixed histology [19]. The recognition,
surveillance and treatment of CDH1 mutation carriers
are extensively described below.
Gastric cancer in familial intestinal gastric cancer and
other hereditary cancer syndromes
Many families with intestinal type GC exhibiting an
autosomal dominant inheritance pattern have beendocumented. However, in such families, disease causing
germline mutations for intestinal GC have not been
found yet.
An increased risk of developing both diffuse and intes-
tinal type GC has been shown in several well known
hereditary cancer syndromes, besides HDGC. These syn-
dromes include Lynch syndrome [20-22], Peutz-Jeghers
syndrome [23], Li-Fraumeni syndrome [24-26], heredi-
tary breast and ovarian cancer [27,28], familial aden-
omatous polyposis (FAP) [29-31], MUTYH-associated
adenomatous polyposis (MAP) [32], juvenile polyposis
syndrome [33], and Cowden syndrome [34]. The life-
time risk of GC in these syndromes varies substan-
tially between populations studied, but is generally
low. For example, although benign gastric abnormal-
ities such as fundic gland polyps develop in approxi-
mately 12.5-84% of FAP patients, only 40% of these
polyps exhibit adenomatous features and an even smaller
percentage (around 0.5%) develops into gastric adenocar-
cinoma [35]. In Lynch syndrome, the lifetime risk of
GC varies between 2.1% in the Netherlands to 30% in
Korea [36]. Clearly, the risk of developing GC in
these syndromes is higher in areas with high inci-
dence of GC in the general population, such as East
Asia, indicating that in these types of hereditary forms of
GC environmental factors may play a substantial role.
Thus, in all these families life style advice is import-
ant, although its effect on GC risk is not precisely
known. In most of the mentioned syndromes no con-
sensus exists about recommendations of surveillance
of the stomach.Identification of new genes underlying hereditary
gastric cancer
In approximately two thirds of families fulfilling the
strict HDGC criteria, no CDH1 mutation is found and
they remain genetically unexplained. Most of these
families might carry mutations in other, still to be
identified, GC susceptibility genes. As binding partner
for E-cadherin, mutated β- and γ-catenin have been con-
sidered as candidates for diffuse GC predisposition [37].
The β-catenin gene (CTNNB1) was recently assessed in
a series of 40 families with positive history of GC
from the Netherlands without finding any mutations
[Vogelaar et al., unpublished data, 2012].
Also in families with intestinal type GC exhibiting an
autosomal dominant inheritance pattern, genetic suscep-
tibility genes may play a role. No gene has been asso-
ciated with this type of GC yet. In carefully selected
patients next generation sequencing based techniques
that allow for exome or even genome wide detection of
genetic aberrations, might be exploited to unravel gen-
etic predisposition in an unbiased way.
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germline CDH1 mutations
In 1998, Guilford et al. identified germline mutations
in the CDH1 gene as a cause of hereditary diffuse
gastric cancer (HDGC) [38]. CDH1 encodes the protein
E-cadherin, which plays an important role in cell–cell
adhesion and the maintenance of epithelial integrity
[39]. The mutation detection rate is approximately 50%
in families with two gastric cancers in first-degree rela-
tives with at least one diffuse gastric cancer (DGC) diag-
nosed before age 50, or three or more DGC in close
relatives diagnosed at any age [18]. The percentage
decreases if also single cases of DGC below the age of
35 are included [17]. Germline CDH1 mutations are
found in all ethnic groups [40]. The most common types
of mutation are small insertions or deletions (35% of the
mutations). Missense mutations occur in 28% of families,
nonsense mutations and splice site mutations are both
observed in 16% of families. Large exonic deletions are
relatively rare, with a frequency of about 5% [41].
For both men and women, CDH1 mutation carriers
have a cumulative risk of gastric carcinoma by 80
years of age of 80%, with a mean age at diagnosis of
40 years. Additionally, women carrying a CDH1 muta-
tion have a 60% lifetime risk for developing lobular
breast cancer [40].Genetic counseling and criteria for CDH1 mutation testing
Genetic counseling is an essential component of the
management of HDGC. It includes the analysis of the
family history of at least three generations and histo-
pathological confirmation of gastric (pre-) malignancies.
The revised international criteria as established by the
International Gastric Cancer Linkage Consortium (IGCLC)
to select patients with an increased risk of familial gastric
cancer for CDH1 mutation testing are shown in Table 1
[40]. Genetic testing is preferably initiated in an affected
relative. In most countries the youngest age at which rela-
tives at risk should be offered testing is set at age 18.
Rare cases of gastric cancer before age 18 have been
reported, but the overall risk of DGC before the age
of 20 is very low [42,43].Table 1 Clinical criteria for testing for CDH1 germline
mutations [40]
• 1 diffuse gastric cancer case below age 40, or
• 2 gastric cancer cases in a family, one confirmed diffuse gastric
cancer below age 50, or
• 3 confirmed diffuse gastric cancer cases in 1st or 2nd degree
relatives independent of age, or
• Personal or family history of diffuse gastric cancer and lobular breast
cancer, with one diagnosis below age 50Proposed mechanism of HDGC initiation
In 2009, Humar and Guilford proposed a mechanism of
HDGC initiation [44]. E-cadherin is known to play an
important role in cell polarity and epithelial tissue archi-
tecture [45,46]. It is proposed that mutations in CDH1
disturb the cell-cell adhesion mediated by E-cadherin,
which causes disruption of the correct spatial organiza-
tion of the cells. This in turn may interfere with pro-
cesses that regulate cell division, such as the orientation
of the mitotic spindle. Abrogated cell polarity may
also lead to the disruption of cell fate determination
[44,47,48]. These disturbed processes can ultimately re-
sult in the displacement of cells with self-renewal cap-
acity into the lamina propria and lead to the formation
of signet ring cell carcinomas with the capacity for sus-
tained cell division and thus to progression [44].
Prophylactic total gastrectomy in CDH1 mutation carriers
Prophylactic gastrectomy is currently the only option to
eliminate risk of GC development in CDH1 mutation
carriers [49]. The prognosis of patients with a proph-
ylactic gastrectomy is very good. The estimated overall
mortality for total gastrectomy is 2–4% with a nearly
100% risk of long-term morbidity. Associated problems
following gastrectomy include abdominal pain after eat-
ing, dumping syndrome, lactose intolerance, fat malab-
sorption and steatorrhoea and postprandial fullness
[40,50-52]. The optimal timing of prophylactic gastrec-
tomy in individuals with CDH1 mutations is not yet
known. Preventive gastrectomy specimens of CDH1 mu-
tation carriers reveal multiple small signet ring cell
lesions with low proliferation rates; few of these lesions
progress to an aggressive carcinoma beyond the muscu-
lar mucosa [53]. It is unknown why only some of these
lesions develop into aggressive carcinomas. No correl-
ation between patient age and number of small signet
ring cell foci has been observed. Blair et al. advise CDH1
mutation carriers with normal gastric biopsies to con-
sider gastrectomy once the individuals are older than 20
years of age [43]. Other authors recommend considering
preventive gastrectomy when the CDH1 mutation carrier
is 5 years younger than the youngest family member with
DGC, which generally means that preventive gastrectomy
is postponed to an age later than 18 years [54].
In case of a preventive gastrectomy, total gastrectomy with
Roux-en-Y reconstruction is recommended. There is no
need for a radical lymph node dissection in the prophylactic
setting since mucosal adenocarcinomas without submucosal
invasion have a low risk of lymph node metastases [55].
Pathological analysis of preventive gastrectomy specimens
Pathological analysis of the entire gastrectomy sample
includes a thorough assessment microscopically with
haematoxylin and eosin (H&E) and a mucin stain, such
Figure 1 Intramucosal signet ring cell carcinoma. a. Typical small
intramucosal focus of a signet ring cell carcinoma in a preventive
gastrectomy specimen from a CDH1 mutation carrier (H&E,
magnification 100x). b. Detail of signet ring cells between normal
foveolar glands and a normal background without signs of gastritis.
(H&E, magnification 200x).
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be helpful as a primary stain, increasing the detection
rate of small invasive signet ring cell foci and reducing
screening time [56]. The ‘Swiss roll’ technique can be
used to include the complete mucosa [57]. The path-
ology report should mention all gastric abnormalities
and localization, as (pre-) malignant lesions, intestinal
metaplasia, dysplasia, inflammation and presence of
H.pylori-associated gastritis. Histological confirmation
of resection margins consisting of proximal esopha-
geal and distal duodenal mucosa is essential, since
new GC can develop in remaining gastric mucosa.
Pathology of HDGC
Pathological mapping of complete gastrectomy speci-
mens has shown that early-stage HDGC is characterized
by the presence of a few to up to hundreds foci of stage
T1a signet ring cell carcinoma (SRCC) restricted to the
superficial lamina propria, without nodal metastases
(Figure 1a and 1b) [43,54,58,59]. The majority of these
foci appear relatively indolent with mitotically inactive
neoplastic cells. These cells are small at the neck-zone
level and usually enlarge towards the surface of the gas-
tric mucosa exhibiting the distinctive signet ring cell
morphology. The proposed histologic model for HDGC
development by Carneiro et al. starts with signet ring
cell carcinoma in situ (Tis), corresponding to the pres-
ence of signet ring cells within the basal membrane, and
a pagetoid spread pattern of signet ring cells below the
preserved epithelium of glands and foveolae within the
basal membrane [60]. This is followed by increased
pagetoid proliferation of signet ring cells and eventually
to invasive carcinoma [60]. Striking is the discrepancy
between the numerous T1a carcinomas and most often
absence of carcinoma in situ (Tis) lesions, indicating that
invasion usually occurs without morphologically detect-
able carcinoma in situ [60]. Background changes in the
gastric mucosa of prophylactic gastrectomy specimens
consist of foveolar hyperplasia, tufting of surface epithe-
lium, vacuolization of surface epithelium and mild
chronic lymphocytic gastritis without H.pylori infection
or intestinal metaplasia [41,60,61]. Advanced HDGC
presents as a poorly differentiated diffuse carcinoma
with sometimes a few signet ring cells (linitis plastica)
but also undifferentiated or mixed subtypes with mucin-
ous and sometimes tubular dedifferentiation are seen
[Van der Post et al., unpublished data, 2012]. These
advanced gastric carcinomas of CDH1 mutation carriers
do not show any characteristics that might discriminate
them from sporadic gastric cancers.
Surveillance endoscopy
The ‘Cambridge surveillance protocol’ is advised for
CDH1 mutation carriers who do not (yet) want toundergo a prophylactic gastrectomy, to individuals at
50% risk of being carrier who are not (yet) willing to be
tested for the mutation as well as for members from
HDGC families without a known CDH1 mutation [62].
This protocol comprises H.Pylori-testing, annual gas-
troscopy with ‘high definition’ endoscope, careful inspec-
tion of mucosa during 30 minutes, insufflation and
desufflation of the stomach, biopsies of mucosal abnor-
malities and 30 random biopsies from different gastric
regions (antrum, angulus, corpus, fundus, cardia) [40].
The endoscopy should be performed using a white light
high definition endoscope in a dedicated session with at
least 30 minutes allocated to allow for a careful inspec-
tion of the mucosa on inflation and deflation, and to
allow time for multiple biopsies to be taken [40]. Use of
mucolytics such as acetylcysteine may be helpful to ob-
tain good views. Endoscopy permits direct inspection
and biopsy of suspicious areas, but diffuse GC is difficult
to detect at an early and treatable stage since the lesions
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exophytic masses. The major problems include difficul-
ties to identify (sub)mucosal lesions and biases in
sampling in macroscopically normal-appearing gastric
mucosa [63]. Such specimens therefore need to be evalu-
ated by pathologists with expertise with this type of
lesions. Several studies have shown that even though
CDH1 mutation carriers had negative biopsies prior to
prophylactic gastrectomy, foci were detected in their gas-
trectomy specimens [49,53,58,59]. Other techniques, such
as chromoendoscopic techniques, trimodal imaging, con-
focal endomicroscopy and molecular imaging techniques
are currently not recommended, but need to be further
explored in a research setting [40].
Conclusion
The overall incidence of GC is declining, which is most
likely due to the reduction in environmental risk factors.
Germline mutations in the CDH1 gene have been identi-
fied as an important cause of HDGC, but still in more
than two thirds of strictly selected HDGC families
the genetic cause remains unknown. Additionally, the
genetic basis of familial cases with an intestinal type
gastric cancer is largely unknown. Elucidation of novel
gastric cancer susceptibility genes will be an important
step towards additional options for gastric cancer pre-
vention. Therefore, identifying new genetic gastric cancer
predisposing factors is one of the important targets in
the near future.
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